高等学校化学学报 ›› 2020, Vol. 41 ›› Issue (5): 884.doi: 10.7503/cjcu20190714

• 庆祝《高等学校化学学报》复刊40周年专栏 • 上一篇    下一篇

聚金属氧酸盐在阿尔兹海默症治疗中的新进展

马蒙蒙1,2,曲晓刚1,*()   

  1. 1. 中国科学院长春应用化学研究所稀土资源利用国家重点实验室, 化学生物学实验室, 长春 130022
    2. 中国科学技术大学应用化学与工程学院, 合肥 230026
  • 收稿日期:2019-12-27 出版日期:2020-05-10 发布日期:2020-03-23
  • 通讯作者: 曲晓刚 E-mail:xqu@ciac.ac.cn
  • 基金资助:
    国家自然科学基金(21431007);国家自然科学基金(21533008);中国科学院前沿科学项目(QYZDJ-SSW-SLH052)

Recent Advances on Polyoxometalates as Metallodrug Agents for Alzheimer’s Disease

MA Mengmeng1,2,QU Xiaogang1,*()   

  1. 1. State Key Laboratory of Rare Earth Resource Utilization, Laboratory of Chemical Biology,Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
    2. College of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China
  • Received:2019-12-27 Online:2020-05-10 Published:2020-03-23
  • Contact: Xiaogang QU E-mail:xqu@ciac.ac.cn
  • Supported by:
    † Supported by the National Natural Science Foundation of China(21431007);† Supported by the National Natural Science Foundation of China(21533008);the Key Program of Frontier of Sciences, Chinese Academy of Sciences(QYZDJ-SSW-SLH052)

摘要:

从聚金属氧酸盐(POMs)对β-淀粉样蛋白(Aβ)聚集的调控作用、 水解及光动力治疗等方面介绍其在阿尔兹海默症(AD)治疗中的最新研究进展, 为进一步研究POMs抗AD药物活性提供了参考.

关键词: 阿尔兹海默症, 聚金属氧酸盐, β-淀粉样蛋白

Abstract:

Alzheimer’s disease(AD) is a progressive neurodegenerative disorder characterized by cognitive dysfunction and memory loss. Although the exact pathogenesis of AD remains unclear, recent evidences have demonstrated that the accumulation and deposition of β-amyloid peptide(Aβ) is a key step in AD pathogenesis. Polyoxometalates(POMs) have the merits of adjustable structures, ease of preparation, and low cost, and thus have shown promising in AD treatment. Hence, recent advances on the POMs as a novel AD metallodrug agent are summarized.

Key words: Alzheimer’s disease, Polyoxometalates, β-Amyloid

中图分类号: 

TrendMD: